{"title":"Report from the 17th Conference on Retroviruses and Opportunistic Infections. CCR5 antagonists--out with the old, in with the new?","authors":"H. Albrecht","doi":"10.1056/AC201003150000008","DOIUrl":null,"url":null,"abstract":"Maraviroc — the only currently licensed CCR5 antagonist — has proven effective in both treatment-naive and treatment-experienced patients but is","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"12 1","pages":"32"},"PeriodicalIF":0.0000,"publicationDate":"2010-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal watch. AIDS clinical care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/AC201003150000008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Maraviroc — the only currently licensed CCR5 antagonist — has proven effective in both treatment-naive and treatment-experienced patients but is
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
